Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles

Abstract:
Nanovalent Pharmaceuticals of Bozeman, Montana has entered into a collaboration with oncology researchers at Children's Hospital of Los Angeles. The partnership will focus on generating efficacy data in murine models of Ewing's Sarcoma and Acute Lymphoblastic Leukemia utilizing Nanovalent's drug candidates NANO-EW and NANO-ALL.

NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles

Bozeman, MT | Posted on December 1st, 2007

NANO-EW, NanoValent's lead cancer drug candidate is a transferrin surface targeted nanoparticle loaded with the chemotherapeutic SN38. The Company's primary indication is Ewing's Sarcoma. However, the firm intends to expand development efforts to include non-small cell lung cancer and hepatocellular carcinoma.

NANO-ALL is a transferrin surface targeted nanoparticle delivering siRNA fragments intended to silence gene sequences specific to acute lymphoblastic leukemia.

The Company is developing therapeutics against pediatric and adult cancers using proprietary polymerized liposomal nanoparticle (PLN) drug delivery technology.

####

About Nanovalent Pharmaceuticals
NanoValent Pharmaceuticals, Inc. (NVP) is a Delaware C-corporation commercializing a drug delivery platform that differentiates itself from other particle delivery systems through several key features. NanoValent particles are highly robust, customizable, stable, cheap, and easy to manufacture. The technology is capable of delivering a wide array of drug molecules or drug cocktails using multiple tissue targeting ligands. While other firms have successfully used targeted particles to deliver pharmaceuticals, few competitors have a payload specific custom offering with the flexibility to target using any surface ligand and deliver virtually any drug or biological payload. The platform product and manufacturing protocols are complete and the company has secured patents along with significant grant funding. The Company’s strategy is to develop several internal delivery programs, while leveraging the versatility of the platform technology providing custom drug delivery solutions to academic and private drug development programs. Internal development efforts are focused on vaccines, cancer therapeutics, and RNAi delivery.

Contacts:
James Hamilton MD, MBA
President


Jon Nagy PhD
Lead Scientist


Tim Trich MD, PhD
Chief Medical Officer

Copyright © NanoValent Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Design of micro and nanoparticles to improve treatments for Alzheimers and Parkinsons: At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs October 20th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Announcements

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Alliances/Partnerships/Distributorships

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

IRLYNX and CEA-Leti to Streamline New CMOS-based Infrared Sensing Modules Dedicated to Human-activities Characterization October 15th, 2014

New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE